

Curriculum Vitae - Stefano Alivernini

Name: Stefano Alivernini
Date of birth: 19 September 1980
Nationality: Italian
Current post: Academic Researcher – Consultant in Rheumatology, Institute of Rheumatology, Fondazione Policlinico Universitario A. Gemelli – Catholic University of The Sacred Heart
Employer: Fondazione Policlinico Universitario A. Gemelli – Catholic University of The Sacred Heart

Previous Posts:

2011 –2015 Consultant in Rheumatology, Institute of Rheumatology, Policlinico Universitario A. Gemelli – Catholic University of The Sacred Heart;

2010-2011 Research fellow at the “Institute of Infection, Immunity and Inflammation”, University of Glasgow, United Kingdom

2010 Research fellow at the “Department of Clinical Immunology and Rheumatology”, Academic Medical Centre, Amsterdam;

Qualification:

2016 Master degree in Translational Research in Rheumatology – University of Trieste

2013 PhD in “Clinical Proteomics” at the University of Verona, with the work entitled “The role of miR-34 and miR-22 in the activation of RA monocytes and dendritic cells and its contribution to Rheumatoid arthritis” under the tutorship of Prof. Gianfranco Ferraccioli, Dr. Mariola Kurowska-Stolarska and Prof. Iain B McInnes.

2009 Subspecialty degree in Rheumatology at the Catholic University of the Sacred Heart, Rome, with the work entitled “Analysis of the wound fluid of skin ulcers of patients with Systemic Sclerosis” under the tutorship of Prof. Gianfranco Ferraccioli.

2004 Degree at the School of Medicine at the Catholic University of the Sacred Heart, in Rome” with the work entitled “Study of the TNF-RII polymorphism and cytokines profile in patients with Systemic Sclerosis and cardio-pulmonary involvement”, under the tutorship of Prof. Gianfranco Ferraccioli.

PUBLICATIONS

Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?

Alivernini S, Tolusso B, Petricca L, Bui L, Di Sante G, Peluso G, Benvenuto R, Fedele AL, Federico F, Ferraccioli G, Gremese E. Ann Rheum Dis. 2017 Jan 24.

microRNA-155 influences B cell function through PU.1 in Rheumatoid Arthritis. **Alivernini S**, Kurowska-Stolarska M, Tulusso B. et al. Nature Communications 2016 Sep 27;7:12970.

Sfriso P, Priori R, Valesini G, Rossi S, Montecucco CM, D'Ascanio A, Carli L, Bombardieri S, La selva G, Iannone F, Lapadula G, **Alivernini S** et al. Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol 2016;35:1683-9.

Immunosuppressive therapy (methotrexate or cyclophosphamide) in combination with corticosteroids in the treatment of Giant Cell Arteritis: comparison with glucocorticoids alone. Carbonella A, Berardi G, Petricca L, Biscetti F, **Alivernini S** et al. J Am Geriatr Soc. 2016;64:672-374.

Biomolecular features of inflammation in obese rheumatoid arthritis patients: management consideration. Tulusso B, Gigante MR, **Alivernini S** et al. Exp Rev Clin Immunol 2016;12:751-62.

Collagen specific T-cell repertoire and HLA-DR alleles: biomarkers of active refractory rheumatoid arthritis. Di Sante G, Tulusso B, Fedele AL, Gremese G, **Alivernini S** et al. EBiomedicine 2015;17:2037-45.

Tapering and discontinuation of TNF-alpha blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission. **Alivernini S**, Peluso G, Fedele AL, Tulusso B, Gremese E, Ferraccioli G. Arthritis Research and Therapy 2016, 3;18-19.

CTLA-4 Ig as an effective treatment in a patient with type I diabetes mellitus and seropositive rheumatoid arthritis. Fedele AL, **Alivernini S**, Gremese E, Ferraccioli G. Clin Exp. Rheumatol 2016;34:315-7.

Biomarkers of joint damage in rheumatoid arthritis: where are we in 2013? Ferraccioli G, **Alivernini S**, Gremese E. J Rheumatol. 2013 Aug;40(8):1244-6

Rheumatoid arthritis and Alzheimer's disease: genetic and epigenetic links in inflammatory regulation. Ferraccioli G, Carbonella A, Gremese E, **Alivernini S**. Discov Med. 2012 Dec;14(79):379-88.

ZAP-70+ B cell subset influences response to B cell depletion therapy and early repopulation in rheumatoid arthritis. Gremese E, Tulusso B, Fedele AL, Canestri S, **Alivernini S**, Ferraccioli G. J Rheumatol. 2012 Dec;39(12):2276-85.

Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Caporali R, Conti F, **Alivernini S**, Atzeni F, Serio B, Cutolo M, Valesini G, Ferraccioli G, Sarzi-Puttini P, Salvarani C, Guiducci S, Zampogna G, Gremese E, Pipitone N, Scrivo R, Bugatti S, Montecucco C, Matucci-Cerinic M. Clin Exp Rheumatol. 2011 May-Jun;29(3 Suppl 66):S7-14.

PTPN22 1858C>T Polymorphism Distribution in Europe and Association with Rheumatoid Arthritis: Case-Control Study and Meta-Analysis. Totaro MC, Tulusso B, Napolioni V, Faustini F, Canestri S, Mannocci A, Gremese E, Bosello SL, **Alivernini S**, Ferraccioli G. PLoS One. 2011;6(9):e24292.

MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Kurowska-Stolarska M, **Alivernini S**, Ballantine LE, Asquith DL, Millar NL, Gilchrist DS, Reilly J, Ierna M, Fraser AR, Stolarski B, McSharry C, Hueber AJ, Baxter D, Hunter J, Gay S, Liew FY, McInnes IB. Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11193-8.

B cell subsets in the joint compartments of seropositive and seronegative RA and non-RA arthritides express memory markers and ZAP-70 and characterize the aggregate pattern irrespectively of the autoantibody status. Michelutti A, Gremese E, Morassi F, Petricca L, Arena V, Tulusso B, **Alivernini S**, Peluso G, Bosello SL, Ferraccioli G. Mol Med. 2011 May 13.

Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease. De Santis M, Bosello SL, Peluso G, Pinnelli M, **Alivernini S**, Zizzo G, Bocci M, Capacci A, La Torre G, Mannocci A, Pagliari G, Varone F, Pistelli R, Danza FM, Ferraccioli G. Clin Respir J. 2010 Nov 25

Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. van de Sande MGH, Gerlag DM, Lodde BM, van Baarsen LGM, **Alivernini S**, Codullo V, Felea I, Vieira-Sousa E, Fearon U, Reece R, Montecucco C, Veale DJ, Pitzalis C, Emery P, Klareskog L, McInnes IB, Tak PP. Ann Rheum Dis (2010) Nov 24.

Interleukin-1 β and Interleukin-6 in Arthritis Animal Models: Roles in the Early Phase of Transition from Acute to Chronic Inflammation and Relevance for Human Rheumatoid Arthritis. Ferraccioli F, Bracci-Laudiero L, **Alivernini S**, Gremese E, Tulusso B, De Benedetti F. MOL MED 2010. 16(11-12)552-557

ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. **Alivernini S**, Laria A, Gremese E, Zoli A, Ferraccioli G. Arthritis Res Ther. 2009;11(6):R163. Epub 2009 Nov 3.

Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment. **Alivernini S**, Mazzotta D, Zoli A, Ferraccioli G. Drugs Aging. 2009;26(5):395-402.

Skin ulcers in systemic sclerosis: determinants of presence and predictive factors of healing. **Alivernini S**, De Santis M, Tulusso B, Mannocci A, Bosello SL, Peluso G, Pinnelli M, D'Antona G, LaTorre G, Ferraccioli G. J Am Acad Dermatol. 2009 Mar;60(3):426-35.

Lupus anticoagulant and ischemic myocardial microangiopathy in rheumatoid arthritis. Ferraccioli G, Zoli A, **Alivernini S**, De Santis M, Verrillo A, Loperfido F. Nat Clin Pract Cardiovasc Med. 2006 Jun;3(6):339-43

Raccomandazioni per l'utilizzo di farmaci biologici nella gestione dei pazienti con Artrite Reumatoide. Caporali R, Conti F, **Alivernini S**, Atzeni F, Seriola B, Cutolo M, Valesini G, Ferraccioli G, Sarzi-Puttini P, Salvarani C, Guiducci S, Zampogna G, Gremese E,

Pipitone N, Scrivo R, Bugatti S, Montecucco C, Matucci-Cerinic M. Reumatismo 2012 64(suppl 1):7-16.

Italian consensus on the recommendations about the use of methotrexate for the treatment of rheumatic diseases with a focus on rheumatoid arthritis: results from the "3E initiative".

De Leonardis F, **Alivernini S**, Bonacci E, Buono AM, Bombardieri S, Ferraccioli GF, Montecucco C, Sinigaglia L, Trotta F, Valentini G. Reumatismo 2010 62(1):34-45.

Citrullination: the loss of tolerance and development of autoimmunity in rheumatoid arthritis.

Alivernini S, Fedele AL, Cuoghi I, Toluoso B, Ferraccioli G. Reumatismo. 2008 Apr-Jun;60(2):85-94

S Alivernini, E Gremese, G Ferraccioli. NSAIDs in Rheumatoid Arthritis Today. Addressing unmet medical needs in Rheumatoid Arthritis. 2012. Elsevier (p1-10) (*Chapter in book*).

S Alivernini, E Gremese, G Ferraccioli. Drugs in Focus in arthritis: Leflunomide. In Scientific Basis of Healthcare: Arthritis. (p158-180) 2011(*Chapter in book*).

S Alivernini, E Gremese, G Ferraccioli. Drugs in Focus in arthritis: an overview. In Scientific Basis of Healthcare: Arthritis. (p134-157) 2011 (*Chapter in book*).